These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 17377585)

  • 1. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
    Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
    Tang TC; Chang H; Chuang WY
    Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
    Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
    Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
    Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
    Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
    Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
    Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
    Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia.
    Alrwas A; Quesada JR; Marcos LA; Mehta SS; Shattuck BL; Nguyen ND; Juneja HS
    Cancer Genet; 2012 Oct; 205(10):519-22. PubMed ID: 22944561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
    Shah S; Loghavi S; Garcia-Manero G; Khoury JD
    J Hematol Oncol; 2014 Mar; 7():26. PubMed ID: 24669761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
    Pardanani A; Brockman SR; Paternoster SF; Flynn HC; Ketterling RP; Lasho TL; Ho CL; Li CY; Dewald GW; Tefferi A
    Blood; 2004 Nov; 104(10):3038-45. PubMed ID: 15284118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
    Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
    [No Abstract]   [Full Text] [Related]  

  • 15. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
    Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
    Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia].
    Zhang Y; Qin TJ; Zhou CL; Liu L; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):381-4. PubMed ID: 19951530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Ng HJ; Tan DC; Yiu RC; How GF
    Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
    Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
    Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.